文献速递心力衰竭与心肌病

免疫检查点抑制剂相关心肌炎的临床诊治策略:叙述性综述

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
PubMed 文献 · JAMA Cardiol · 2021-01-01

本文综述免疫检查点抑制剂(ICI)相关心肌炎的临床表现、诊断与治疗。该不良反应显著且可能致命,临床表现与心脏病理差异很大;心内膜心肌活检为金标准,但常需结合临床怀疑、心脏生物标志物(尤其是肌钙蛋白)和心脏影像综合诊断。CTLA-4抑制剂联合PD-1或PD-L1抑制剂会增加发病风险;本文提出标准化诊治路径。

要点

  • 疑似ICI相关心肌炎需结合近期肿瘤治疗史、查体、心脏生物标志物和影像综合评估。
  • 心内膜心肌活检是诊断金标准,但常需与临床、生物标志物和影像联合支持诊断。
  • CTLA-4抑制剂联合PD-1或PD-L1抑制剂会增加ICI相关心肌炎风险。

核心结论

  • 本文提出针对疑似ICI相关心肌炎的标准化诊断与治疗路径。
  • 完整采集近期肿瘤治疗史并结合查体、心脏生物标志物、心脏影像和心内膜心肌活检,是多数病例的实用诊断方法。
  • 新型生物标志物或影像模态的加入仍在积极研究中,需在更大队列中评估。

研究设计与样本

  • 叙述性综述,总结当前关于ICI相关心肌炎的文献。
  • 纳入对象为接受ICI治疗并可能发生ICI相关心肌炎的患者。

主要发现

  • ICI相关心肌炎患者的临床表现与心脏病理表现差异很大。
  • 心内膜心肌活检是诊断金标准。
  • 诊断常需临床怀疑、心脏生物标志物(尤其是肌钙蛋白)和心脏影像与活检联合支持。
  • CTLA-4抑制剂联合PD-1或PD-L1抑制剂会增加ICI相关心肌炎的发生风险。

关键数值与推荐

  • 心内膜心肌活检为ICI相关心肌炎诊断的金标准。
  • 诊断常需联合临床怀疑、心脏生物标志物(尤其是肌钙蛋白)、心脏影像与活检。
  • CTLA-4抑制剂联合PD-1或PD-L1抑制剂增加ICI相关心肌炎风险。

临床怎么用

  • 对疑似ICI相关心肌炎患者,应详细采集近期肿瘤治疗史并查体。
  • 结合心脏生物标志物、心脏影像与心内膜心肌活检进行综合诊断。
  • 按本文提出的标准化诊断与治疗路径管理疑似病例。

局限性

  • 新型生物标志物或影像模态的价值尚待更大队列研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the last decade, immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancer types. Immune checkpoint inhibitor-associated myocarditis has emerged as a significant and potentially fatal adverse effect. Recognizing, diagnosing, and treating ICI-associated myocarditis poses new challenges for the practicing clinician. Here, the current literature on ICI-associated myocarditis is reviewed. OBSERVATIONS: Clinical presentation and cardiac pathological findings are highly variable in patients with ICI-associated myocarditis. Although endomyocardial biopsy is the criterion standard diagnostic test, a combination of clinical suspicion, cardiac biomarkers (specifically troponin), and cardiac imaging, in addition to biopsy, is often needed to support the diagnosis. Importantly, the combination of a cytotoxic T-lymphocyte-associated protein 4 inhibitor with a programmed cell death protein 1 or programmed death-ligand 1 inhibitor increases the risk of developing ICI-associated myocarditis. CONCLUSION AND RELEVANCE: This review aims to provide a standardized diagnostic and therapeutic approach for patients with suspected ICI-associated myocarditis. A complete history of recent cancer treatments and physical examination in combination with cardiac biomarkers, cardiac imaging, and endomyocardial biopsy represent a pragmatic diagnostic approach for most cases of ICI-associated myocarditis. The addition of novel biomarkers or imaging modalities is an area of active research and should be evaluated in larger cohorts.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lehmann LH, Cautela J, Palaskas N, et al. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. JAMA Cardiol. 2021. PMID: 34232253. doi:10.1001/jamacardio.2021.2241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。